Safety and immunogenicity of an hiv-1 prefusion-stabilized envelope trimer (trimer 4571) vaccine in healthy adults: a first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial

HIGHLIGHTS

• who: Katherine V. Houser from the USA USA USA have published the research: Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial, in the Journal: (JOURNAL) of September/11,/2019
• what: This approach has recently been successfully utilized to create a protein subunit vaccine against respiratory syncytial virus as well as mRNA_vaccines encoding SARS-CoV-2 spike_proteins . The authors report the safety and vaccine-induced antibody response results from this first-in-human phase . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.